Showing posts with label provenge prostate cancer. Show all posts
Showing posts with label provenge prostate cancer. Show all posts

Tuesday, April 14, 2009

Dendreon

Dendreon is a company that's really been through it, as have their investors. Many will remember the upheaval back in 2007, when the company showed what they felt were impressive results for their autologous prostate cancer immunotherapy Provenge, got a favorable reception from the FDA's advisory panel, but were then hit with an "approvable" letter asking for more data. (Here are three posts on that: before, during, and after).
Dendreon’s long-awaited big news is coming tomorrow morning. The Seattle biotech company (NASDAQ: DNDN) said it will hold a conference call before stock trading opens tomorrow morning to discuss the final results of a clinical trial that will show whether its immune-stimulating drug for prostate cancer, Provenge, can help men live longer.
The company’s conference call will start at 9 am Eastern time/6 am Pacific, about a half-hour before trading opens. The company didn’t tip its hand one way or another in its statement today, but it’s important enough that trading was halted in the stock prior to the announcement. Plenty of people are already betting big that Dendreon is going to have positive results from this trial, called Impact, of 500 with terminal prostate cancer. Shares climbed 16 percent today to close at $7.30, on about quadruple the average trading volume.
Bookmark and Share